Last reviewed · How we verify
IV saline 0.9%
IV saline 0.9% restores fluid and electrolyte balance by providing isotonic sodium chloride solution that matches blood osmolality.
IV saline 0.9% restores fluid and electrolyte balance by providing isotonic sodium chloride solution that matches blood osmolality. Used for Hypovolemia and fluid resuscitation, Maintenance fluid therapy, Vehicle for intravenous medication administration.
At a glance
| Generic name | IV saline 0.9% |
|---|---|
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Drug class | Crystalloid fluid / Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Fluid & Electrolyte Management |
| Phase | Phase 3 |
Mechanism of action
Normal saline (0.9% NaCl) is an isotonic crystalloid fluid that does not cause fluid shifts between intracellular and extracellular compartments. It replaces lost intravascular volume and maintains electrolyte homeostasis, making it a foundational fluid resuscitation therapy. It is used across multiple therapeutic contexts including volume replacement, medication dilution, and maintenance fluid therapy.
Approved indications
- Hypovolemia and fluid resuscitation
- Maintenance fluid therapy
- Vehicle for intravenous medication administration
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypernatremia
- Phlebitis at infusion site
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (PHASE3)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Improving Preterm Kidney Outcomes With Caffeine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |